Anzeige
Mehr »
Sonntag, 29.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40FFK | ISIN: US0050831009 | Ticker-Symbol:
NASDAQ
27.06.25 | 21:59
5,900 US-Dollar
+1,37 % +0,080
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTUATE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ACTUATE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ACTUATE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoACTUATE THERAPEUTICS, INC. - 8-K, Current Report3
DiActuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial2
20.06.Actuate Therapeutics identifies biomarkers for pancreatic cancer drug1
20.06.Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO101CHICAGO and FORT WORTH, Texas, June 20, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing...
► Artikel lesen
16.06.Actuate Therapeutics to be included in Russell 3000, Russell 2000 indexes1
ACTUATE THERAPEUTICS Aktie jetzt für 0€ handeln
16.06.Actuate Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes1
02.06.ASCO: Actuate's pancreatic cancer drug boosts survival by 3 months in phase 2 study3
02.06.ACTUATE THERAPEUTICS, INC. - 8-K, Current Report2
01.06.Actuate Therapeutics, Inc. (ACTU)'s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer2
31.05.Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer2
31.05.Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic ...60Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously...
► Artikel lesen
23.05.ACTUATE THERAPEUTICS, INC. - 8-K, Current Report4
22.05.Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer2
15.05.ACTUATE THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
06.05.ACTUATE THERAPEUTICS, INC. - 8-K, Current Report2
23.04.Actuate Therapeutics: Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting1
22.04.Craig-Hallum sets $21 target on Actuate Therapeutics stock1
17.04.Actuate Therapeutics: Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 20251
13.03.ACTUATE THERAPEUTICS, INC. - 10-K, Annual Report1
25.02.Actuate meldet Fortschritte bei Bauchspeicheldrüsenkrebs-Studie3
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1